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Abstract
Introduction: In general, ocular complications of hematologic malignancies such as leukemia are
well documented. However, reports of ocular involvement in such diseases as lymphomatoid
granulomatosis and chronic myelomonocytic leukemia are uncommon. Here we present cases of
these two relatively rare hematologic malignancies demonstrating clinical and subclinical ocular
involvement.
Case Presentation: In the first case, a 54-year-old man with a previous diagnosis of
lymphomatoid granulomatosis presented with a new-onset conjunctival lesion while his systemic
disease was thought to be in remission. A biopsy was taken that revealed heavy infiltrates of B and
T cells at the site of the lesion. Molecular analysis confirmed that these cells were positive for both
Epstein-Barr viral DNA and immunoglobulin heavy chain gene rearrangement, consistent with a
manifestation of his systemic disease. In the second case, a 51-year-old man with chronic
myelomonocytic leukemia died after a waxing and waning clinical course. Post-mortem studies
revealed the presence of atypical monocytes in the choroidal and subretinal spaces, consistent with
his previous diagnosis.
Conclusion: While ocular involvement in hematologic malignancies is not uncommon, these two
cases describe involvement of the eye by two relatively rare neoplasms. We herein emphasize
novel findings in each case, including conjunctival involvement as the first sign of recurrent
lymphomatoid granulomatosis and the combination of subretinal and choroidal myelomonocytic
leukemic infiltration. With the evolution of new antineoplastic therapies that may prolong life, these
cases exemplify the importance of eye care in patients diagnosed with hematologic malignancies.
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Introduction
Ocular complications of hematologic malignancies such
as leukemia are well documented. It is estimated that 50%
or more of all leukemias manifest some form of ocular
involvement [1,2]. Here we present the cases of two
patients with relatively rare hematologic malignancies
with notable pre- or post-mortem demonstrating clinical
and pathological ocular involvement.
Case presentation
Case 1
A 54 year-old man with a previous diagnosis of lympho-
matoid granulomatosis (LYG) presented with a left con-
junctival growth consisting of clusters of papillae with
focal hemorrhages of several weeks' duration (Figure 1A),
during which time the systemic disease was thought to be
in remission. The lesion was subsequently biopsied (Fig-
ure 1B). Given the patient's clinical history and the dense
infiltrate of pleomorphic lymphoid cells in the tissue,
immunohistochemistry was performed using antibodies
against B-cell (CD20; Figure 1C), T-cell (CD45R0), and
macrophage (CD68) markers. B-cell monoclonality was
demonstrated using primer pairs FR3A, FR2A, and CDR3
for immunoglobulin heavy chain (IgH) regions [3], while
PCR showed the presence of Epstein-Barr virus (EBV)
DNA in the cells comprising the inflammatory infiltrate
(Figure 1D). Based on the predominance of B- and T-cell
infiltrates in the lesion, positive IgH rearrangement, and
the presence of EBV DNA by PCR analysis, the patient's
underlying disease was considered as a potential cause. He
received palliative radiotherapy to the orbit.
Case 2
A 51 year-old man with chronic myelomonocytic leuke-
mia developed progressively worsening anemia, throm-
bocytopenia, and leukocytosis and subsequently expired.
Post-mortem gross examination of the eyes was signifi-
cant for multiple fresh and old retinal hemorrhages bilat-
erally. Microscopic examination revealed numerous
atypical leukocytes within the choroidal vasculature (Fig-
ure 2A) and bilateral retinal hemorrhages, as well as a
small focus of subretinal leukemic cells with admixed
hemorrhage in the left eye (Figure 2C). The leukemic cells
within the choroidal vasculature and in the subretinal
lesion were strongly immunopositive for macrophage
marker, CD68 (Figures 2B &2D). Molecular studies dem-
onstrated negative IgH gene rearrangement and absence
of EBV DNA.
Discussion
The first case demonstrates a LYG metastatic lesion to the
conjunctiva. First described as a distinct clinical entity in
1972, LYG is a rare, angiocentric, angiodestructive disease
that is infrequently associated with ocular manifestations
[4]. Though rare, the most commonly recognized pathol-
ogy is consistent with the biopsy in this case, marked by
the diffuse presence of B cells with an exuberant, attend-
ant T-cell response. Current research suggests that LYG
may be categorized as an EBV-related B-cell lymphoma
[5]. This conjunctival lesion, confirmed immunohisto-
chemically and molecularly, was the first clinical sign of
LYG recurrence detected in this patient.
It should be noted that although ocular manifestations in
LYG are uncommon, case reports do exist that document
involvement of structures including the optic nerve [6],
retina, sclera, and eyelid. Conjunctival involvement has
also previously been described [7]. Reported clinical man-
ifestations vary according to the ocular structure involved,
but are generally diverse, ranging from ulcerative skin
nodules [7] to sudden unilateral blindness to uveitis.
The second case involves a patient with chronic myelo-
monocytic leukemia (CMML), a disease formerly classi-
fied solely as a type of myelodysplastic syndrome (MDS)
but reclassified in 1999 as a mixed MDS/myeloprolifera-
tive disorder [8].
Myelodysplastic syndrome (MDS) is a term that refers to
a heterogeneous group of clonal bone marrow disorders
associated with changes in marrow cellularity accompa-
nied by dysmyelopoiesis and peripheral blood cytopenias
[9]. Many case reports exist in the literature demonstrating
ocular involvement in patients with MDS. In a 2005 retro-
spective study, Kezuka et al. reported that nearly half of 41
patients with MDS studied went on to develop ocular
complications including corneal ulcer, iridocyclitis, vitre-
ous hemorrhage, retinal hemorrhage, nerve-fiber layer
infarcts, and optic neuritis [10].
In contrast to MDS, ocular involvement in patients with
CMML is rarely reported, perhaps owing in part to the fact
that the severe, progressive illness faced by many of these
patients limits the feasibility of ocular examinations.
While the patient described in the second case had no
documented visual symptoms, pathology demonstrates
infiltration of atypical cells within the vasculature of the
choroid bilaterally as well as a subretinal hemorrhage
with leukemic infiltration in the left eye. To our knowl-
edge, this combination of findings in a patient with
CMML has not been previously reported.
Conclusion
We herein describe several microscopic ocular pathologic
findings associated with two relatively rare hematologic
malignancies. These cases emphasize both the ability of
these diseases to demonstrate ocular involvement as well
as important clinical and subclinical findings that may be
seen with each. Furthermore, we emphasize the impor-
tance of an awareness of newly recognized manifestationsJournal of Medical Case Reports 2007, 1:158 http://www.jmedicalcasereports.com/content/1/1/158
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Case 1 Figure 1
Case 1. (A) Generalized conjunctival injection, chemosis and a prominent lesion with elevated, polygonal, hyperemic mounds 
and small hemorrhages are seen in the superior bulbar conjunctiva. (B) A dense infiltration of cells and several foci of necrosis 
are present, as is hemorrhage into the conjunctival parenchyma. The inset demonstrates pleomorphism and prominence of 
nucleoli. (C) Immunohistochemistry demonstrates strongly immunopositive staining for B-cell marker, CD20. (D) Gel electro-
phoresis reveals: (lane 1) positive bands are indicative of IgH gene rearrangements for B-cell lymphoma. EBV DNA is detected 
in the lymphoma cells. (Lane 3 = negative control, lane 4 = positive control). (B, hematoxylin & eosin, original magnification × 





Case 2 Figure 2
Case 2. (A and B) Choroidal vessels are filled with atypical cells (arrows), which are CD68+. (C) A subretinal infiltrate of leuke-
mic cells (arrows), admixed with hemorrhage, is also seen. (D) The subretinal infiltrate and choroidal vessels contain a signifi-
cant number of CD68+ cells (arrows). R = retina, Ch = choroid. (A and C, hematoxylin & eosin; B and D, avidin-biotin-
complex immunoperoxidase; A and B, original magnification × 100; C and D, original magnification × 200).
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of disease in cases such as these. In particular, the advent
of novel antineoplastic therapies, with their associated
potential to prolong life, may lead to the recognition of
previously unobserved clinical signs. Our pathologic find-
ings support that a routine eye examination, when possi-
ble, should be encouraged for patients with hematologic
malignancies.
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